Biodesix (BDSX) Accounts Payables (2019 - 2026)

Biodesix has reported Accounts Payables for 8 years, with the latest figure at $3.7 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 24.82% year-over-year to $3.7 million; the trailing twelve-month figure through Mar 2026 stood at $3.7 million (up 24.82% YoY), and the FY2025 full-year result was $3.1 million, up 40.38% from the prior year.
• Accounts Payables for Q1 2026 stood at $3.7 million, up from $3.1 million in the prior quarter.
• The five-year high for Accounts Payables was $3.7 million in Q1 2026, with the low at $1.6 million in Q1 2023.
• Historically, Accounts Payables has averaged $2.6 million across 5 years, with a median of $2.9 million in 2023.
• Annual changes were most pronounced in 2022 — Accounts Payables sank 43.42% — and 2024, when it surged 105.57%.
• Biodesix's Accounts Payables stood at $1.7 million in 2022, then soared by 73.83% to $2.9 million in 2023, then declined by 25.09% to $2.2 million in 2024, then soared by 40.38% to $3.1 million in 2025, then rose by 18.54% to $3.7 million in 2026.
• The last three Accounts Payables figures came in at $3.7 million (Q1 2026), $3.1 million (Q4 2025), and $3.6 million (Q3 2025), per Business Quant data.